Captrust Financial Advisors Boosts Stock Position in Avantor, Inc. (NYSE:AVTR)

Captrust Financial Advisors grew its stake in shares of Avantor, Inc. (NYSE:AVTR) by 26.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 17,852 shares of the company’s stock after buying an additional 3,733 shares during the period. Captrust Financial Advisors’ holdings in Avantor were worth $462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Blue Trust Inc. lifted its holdings in shares of Avantor by 1,830.3% in the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares in the last quarter. UMB Bank n.a. purchased a new stake in Avantor in the 3rd quarter worth approximately $49,000. Nisa Investment Advisors LLC lifted its stake in Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after purchasing an additional 835 shares in the last quarter. GAMMA Investing LLC lifted its stake in Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its stake in Avantor by 278.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock worth $130,000 after purchasing an additional 3,700 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. UBS Group lowered their price objective on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, October 8th. Barclays lowered their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Robert W. Baird lowered their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Finally, Wells Fargo & Company lowered their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $27.69.

Avantor Stock Performance

Shares of AVTR stock opened at $22.53 on Friday. The company’s 50-day moving average is $22.59 and its 200 day moving average is $23.55. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company has a market capitalization of $15.33 billion, a price-to-earnings ratio of 48.98, a price-to-earnings-growth ratio of 2.59 and a beta of 1.29.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.